Article · Wikipedia archive · Last revised Jul 19, 2026

Conveglipron

Conveglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus. It is taken orally. The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals. Conveglipron is under development by Huadong Medicine in China. As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.

Last revised
Jul 19, 2026
Read time
≈ 1 min
Length
276 w
Citations
16
Source
Wikipedia ↗
Conveglipron
Clinical data
Other namesHDM-1002; HDM1002
Routes of
administration		Oral12
Drug classGLP-1 receptor agonist; Antidiabetic agent; Antiobesity agent
Identifiers
  • 2-[[4-[6-[[2-fluoro-4-(oxetan-3-yl)phenyl]methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC33H35FN4O5
Molar mass586.664 g·mol−1
3D model (JSmol)
  • C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C7COC7)F
  • InChI=1S/C33H35FN4O5/c34-27-14-22(25-18-41-19-25)4-5-24(27)20-43-32-3-1-2-28(36-32)21-8-11-37(12-9-21)17-31-35-29-7-6-23(33(39)40)15-30(29)38(31)16-26-10-13-42-26/h1-7,14-15,21,25-26H,8-13,16-20H2,(H,39,40)/t26-/m0/s1
  • Key:SFKAXUUDIGSMBK-SANMLTNESA-N

Conveglipron (INNTooltip International Nonproprietary Name; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus.13245 It is taken orally.12 The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals.5 Conveglipron is under development by Huadong Medicine in China.132 As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.132

References

References

  1. "HDM 1002". AdisInsight. Springer Nature Switzerland AG. 14 January 2026. Retrieved 18 February 2026.
  2. "Conveglipron". OZMOSI.
  3. "Delving into the Latest Updates on Conveglipron with Synapse". Synapse. 11 February 2026. Retrieved 18 February 2026.
  4. Pu J, Huang Y, Wan L, Zhu M, Wei H, Gao H, et al. (October 2025). "First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers". Diabetes, Obesity & Metabolism. 27 (10): 5622–5631. doi:10.1111/dom.16610. PMID 40662378.
  5. Pan H, Zhai W, Zhang Z, Guo L, Dong Z, Zhao M, et al. (2023). "59th EASD Annual Meeting of the European Association for the Study of Diabetes: Hamburg, Germany, 2 - 6 October 2023: Discovery of HDM1002, a selective, potent, oral small-molecule GLP-1R agonist for treatment of type 2 diabetes and obesity". Diabetologia. 66 (Suppl 1): S1–S536 (S316). doi:10.1007/s00125-023-05969-6. hdl:10553/132806. ISSN 0012-186X. Retrieved 18 February 2026.